Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma

Mignote Yilma; Neil Mehta

doi:10.1016/j.soc.2023.06.011

Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma

Surg Oncol Clin N Am. 2024 Jan;33(1):133-142. doi: 10.1016/j.soc.2023.06.011. Epub 2023 Aug 1.

Authors

Mignote Yilma¹, Neil Mehta²

Affiliations

¹ Department of Surgery, University of California San Francisco, 513 Parnassus Avenue, S-321, San Francisco, CA 94143, USA; National Clinician Scholars Program, University of California San Francisco, 513 Parnassus Avenue, S-321, San Francisco, CA 94143, USA. Electronic address: https://twitter.com/mignoteyilmaMD.
² Department of Medicine, University of California San Francisco, Connie Frank Transplant Center, 400 Parnassus Avenue 7th Floor, San Francisco, CA 94143, USA. Electronic address: Neil.mehta@ucsf.edu.

PMID: 37945139
DOI: 10.1016/j.soc.2023.06.011

Abstract

Liver transplantation continues to be the optimal treatment for hepatocellular carcinoma (HCC). Given the limited organ supply, patient selection for liver transplant must carefully balance tumor progression with risk of recurrence posttransplant. There are several pretransplant selection criteria that incorporate biomarkers as well as imaging modality to risk-stratify patients as we continue to look for the optimal transplant cutoff for patients with HCC, which should be transplant-center specific, and account for organ availability and dynamic response to locoregional therapy.

Keywords: AFP; Downstaging; Hepatocellular carcinoma; Liver transplantation; Locoregional therapy; Milan criteria.

Publication types

Review

MeSH terms

Carcinoma, Hepatocellular* / pathology
Chemoembolization, Therapeutic*
Humans
Liver Neoplasms* / pathology
Liver Transplantation*
Neoplasm Staging